A new trading day began on Monday, with Biodesix Inc (NASDAQ: BDSX) stock price up 47.99% from the previous day of trading, before settling in for the closing price of $5.46. BDSX’s price has ranged from $3.44 to $30.22 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 69.26% over the past five years. Meanwhile, its annual earnings per share averaged 22.01%. With a float of $3.81 million, this company’s outstanding shares have now reached $7.95 million.
Biodesix Inc (BDSX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Biodesix Inc is 52.12%, while institutional ownership is 18.05%. The most recent insider transaction that took place on Nov 10 ’25, was worth 99. In this transaction Chief Accounting Officer of this company sold 13 shares at a rate of $7.62, taking the stock ownership to the 936 shares. Before that another transaction happened on Nov 10 ’25, when Company’s Chief Development Officer sold 23 for $7.62, making the entire transaction worth $175. This insider now owns 7,939 shares in total.
Biodesix Inc (BDSX) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -1.2 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 41.37% during the next five years compared to 69.26% growth over the previous five years of trading.
Biodesix Inc (NASDAQ: BDSX) Trading Performance Indicators
Here are Biodesix Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.37, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -2.43 in one year’s time.
